613 related articles for article (PubMed ID: 10782829)
1. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis.
Nonaka T; Kikuchi H; Ikeda T; Okamoto Y; Hamanishi C; Tanaka S
J Rheumatol; 2000 Apr; 27(4):997-1004. PubMed ID: 10782829
[TBL] [Abstract][Full Text] [Related]
2. Control of the chondrocyte fibrinolytic balance by the drug piroxicam: relevance to the osteoarthritic process.
Fibbi G; Serni U; Matucci A; Mannoni A; Pucci M; Anichini E; Del Rosso M
J Rheumatol; 1994 Dec; 21(12):2322-8. PubMed ID: 7699636
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the inhibitory effects of two types (90 kDa and 190 kDa) of hyaluronic acid on the expression of fibrinolytic factors in human synovial fibroblasts.
Nonaka T; Kikuchi H; Sohen S; Fukuda K; Hamanishi C; Tanaka S
Mod Rheumatol; 2002 Jun; 12(2):160-6. PubMed ID: 24383905
[TBL] [Abstract][Full Text] [Related]
4. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Ronday HK; Smits HH; Van Muijen GN; Pruszczynski MS; Dolhain RJ; Van Langelaan EJ; Breedveld FC; Verheijen JH
Br J Rheumatol; 1996 May; 35(5):416-23. PubMed ID: 8646430
[TBL] [Abstract][Full Text] [Related]
5. Ethanol-induced up-regulation of the urokinase receptor in cultured human endothelial cells.
Tabengwa EM; Grenett HE; Benza RL; Abou-Agag LH; Tresnak JK; Wheeler CG; Booyse FM
Alcohol Clin Exp Res; 2001 Feb; 25(2):163-70. PubMed ID: 11236828
[TBL] [Abstract][Full Text] [Related]
6. Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis.
Guiducci S; Del Rosso A; Cinelli M; Perfetto F; Livi R; Rossi A; Gabrielli A; Giacomelli R; Iori N; Fibbi G; Del Rosso M; Cerinic MM
Arthritis Res Ther; 2005; 7(6):R1244-53. PubMed ID: 16277677
[TBL] [Abstract][Full Text] [Related]
7. Effect of heat shock on the expression of urokinase-type plasminogen activator receptor in human umbilical vein endothelial cells.
Fukao H; Hagiya Y; Ueshima S; Okada K; Takaishi T; Izaki S; Matsuo O
Thromb Haemost; 1996 Feb; 75(2):352-8. PubMed ID: 8815589
[TBL] [Abstract][Full Text] [Related]
8. Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Pelletier JP; McCollum R; Cloutier JM; Martel-Pelletier J
Br J Rheumatol; 1992; 31 Suppl 1():19-26. PubMed ID: 1555050
[TBL] [Abstract][Full Text] [Related]
9. Tenidap reduces the level of interleukin 1 receptors and collagenase expression in human arthritic synovial fibroblasts.
Martel-Pelletier J; Mineau F; Tardif G; Fernandes JC; Ranger P; Loose L; Pelletier JP
J Rheumatol; 1996 Jan; 23(1):24-31. PubMed ID: 8838504
[TBL] [Abstract][Full Text] [Related]
10. Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis.
Hsieh YS; Yang SF; Lue KH; Chu SC; Lu KH
J Orthop Res; 2008 Apr; 26(4):475-84. PubMed ID: 17975844
[TBL] [Abstract][Full Text] [Related]
11. Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface.
Cerinic MM; Generini S; Partsch G; Pignone A; Dini G; Konttinen YT; Del Rosso M
Life Sci; 1998; 63(6):441-53. PubMed ID: 9718068
[TBL] [Abstract][Full Text] [Related]
12. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
[TBL] [Abstract][Full Text] [Related]
13. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
[TBL] [Abstract][Full Text] [Related]
14. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium.
Hou WS; Li W; Keyszer G; Weber E; Levy R; Klein MJ; Gravallese EM; Goldring SR; Brömme D
Arthritis Rheum; 2002 Mar; 46(3):663-74. PubMed ID: 11920402
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.
Hsieh YS; Yang SF; Lue KH; Chu SC; Li TJ; Lu KH
J Rheumatol; 2007 Apr; 34(4):785-93. PubMed ID: 17299841
[TBL] [Abstract][Full Text] [Related]
17. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.
Del Rosso A; Cinelli M; Guiducci S; Pignone A; Fibbi G; Margheri F; Gabrielli A; Giacomelli R; Coppini A; Del Rosso M; Matucci Cerinic M
Rheumatology (Oxford); 2005 Oct; 44(10):1255-62. PubMed ID: 15998634
[TBL] [Abstract][Full Text] [Related]
18. Galectin 3 and its binding protein in rheumatoid arthritis.
Ohshima S; Kuchen S; Seemayer CA; Kyburz D; Hirt A; Klinzing S; Michel BA; Gay RE; Liu FT; Gay S; Neidhart M
Arthritis Rheum; 2003 Oct; 48(10):2788-95. PubMed ID: 14558084
[TBL] [Abstract][Full Text] [Related]
19. [Levels of matrix metalloproteinase-3 and urokinase-type plasminogen activator in knee synovial fluids from patients with rheumatoid arthritis and osteoarthritis].
Gotoh H; Yamada H; Yoshihara Y; Kikuchi T; Obata K; Shinmei M
Ryumachi; 1997 Feb; 37(1):3-8. PubMed ID: 9128417
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition of vascular smooth muscle cells derived from urokinase receptor (u-PAR)-deficient mice in the presence of carcinoma cells.
Ueshima S; Fukao H; Okada K; Matsuo O
Thromb Res; 2004; 113(1):41-9. PubMed ID: 15081564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
